Skip to main content
. Author manuscript; available in PMC: 2022 Jan 25.
Published in final edited form as: Med Res Rev. 2014 Mar 21;34(6):1168–1216. doi: 10.1002/med.21315

Figure 7.

Figure 7.

Development of five membered heterocycle-based peptidomimtic inhibitors 27–31. Inhibitors were developed by divalent classical bioisosterism replacement of position 4 methylene unit in previously designed inhibitors with either ether or sulfone moiety. IC50 refers to inhibition of plasmin amidolysis.